Journey Medical Corporation
$5.19
▲
6.68%
2026-04-21 06:24:01
journeymedicalcorp.com
NCM: DERM
Explore Journey Medical Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$147.31 M
Current Price
$5.19
52W High / Low
$9.55 / $4.31
Stock P/E
—
Book Value
$1.17
Dividend Yield
—
ROCE
-14.3%
ROE
-44.03%
Face Value
—
EPS
$-0.47
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
58
Beta
1.04
Debt / Equity
79.73
Current Ratio
1.79
Quick Ratio
1.53
Forward P/E
-86.17
Price / Sales
2.78
Enterprise Value
$142.61 M
EV / EBITDA
-36.44
EV / Revenue
2.31
Rating
Strong Buy
Target Price
$13.25
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | IM Cannabis Corp. | $0.41 | — | $3.13 M | — | 510.44% | -516.26% | $9.7 / $1.75 | $-0.45 |
| 2. | Canopy Growth Corporation | $1.2 | — | $709.79 M | — | -8.06% | -48.5% | $3.28 / $1.18 | $1.49 |
| 3. | Assertio Holdings, Inc. | $18.14 | — | $116.08 M | — | -12.35% | -28.25% | $20.45 / $8.55 | $14.63 |
| 4. | Amneal Pharmaceuticals, Inc. | $13.26 | 58.7 | $4.23 B | — | 14.23% | -80.04% | $15.42 / $7.01 | $-0.23 |
| 5. | Akebia Therapeutics, Inc. | $1.43 | — | $381.73 M | — | 11% | 64.49% | $4.08 / $1.14 | $0.12 |
| 6. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
| 7. | Shuttle Pharmaceuticals Holdings, Inc. | $0.99 | — | $5.7 M | — | -791.36% | -7.91% | $11.25 / $0.5 | $1.13 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 16.08 M | 17.63 M | 15.01 M | 13.14 M | 13.62 M | — |
| Operating Profit | -0.44 M | -1.53 M | -2.88 M | -3.32 M | -2.32 M | — |
| Net Profit | -1.25 M | -2.31 M | -3.8 M | -4.07 M | 1.52 M | — |
| EPS in Rs | -0.06 | -0.11 | -0.18 | -0.19 | 0.07 | -0.12 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 61.86 M | 56.13 M | 79.18 M | 73.67 M |
| Operating Profit | -8.17 M | -18.23 M | 1.07 M | -27.52 M |
| Net Profit | -11.43 M | -14.67 M | -3.85 M | -29.63 M |
| EPS in Rs | -0.54 | -0.69 | -0.18 | -1.39 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 94.59 M | 80.24 M | 76.85 M | 105.16 M |
| Total Liabilities | 62.74 M | 60.17 M | 56.5 M | 88.18 M |
| Equity | 31.85 M | 20.07 M | 20.35 M | 16.98 M |
| Current Assets | 66.87 M | 48.18 M | 56.45 M | 77.68 M |
| Current Liabilities | 37.44 M | 35.17 M | 41.87 M | 66.83 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -12.44 M | -9.13 M | 5.24 M | -13.53 M |
| Investing CF | 0 M | -15 M | -5 M | -20 M |
| Financing CF | 16.23 M | 16.99 M | -4.8 M | 16.46 M |
| Free CF | -12.44 M | -24.13 M | 0.24 M | -33.53 M |
| Capex | — | -15 M | -5 M | -20 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -29.11% | 7.48% | — | — |
| Earnings Growth % | -280.79% | 87% | — | — |
| Profit Margin % | -26.14% | -4.87% | -40.22% | — |
| Operating Margin % | -32.48% | 1.35% | -37.35% | — |
| Gross Margin % | 62.81% | 71.09% | 58.23% | — |
| EBITDA Margin % | -14.96% | 2.43% | -31.47% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.